Skip to main content
. 2023 Nov 22;26(12):108560. doi: 10.1016/j.isci.2023.108560

Figure 1.

Figure 1

Metformin prevented the progression of NAFLD in HFD rats

(A and B) Body weight and liver weight of rats fed with normal diet (ND) or high-fat diet (HFD) without or with metformin (150 mg/kg or 300 mg/kg) intragastrically for 8 weeks. Data are represented as mean ± SEM (n = 6 in each group). Differences among groups were assessed by one-way ANOVA analysis. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

(C and D) Serum ALT and AST of rats fed with normal diet (ND) or high-fat diet (HFD) without or with metformin (150 mg/kg or 300 mg/kg) intragastrically for 8 weeks. Data are represented as mean ± SEM (n = 6 in each group). Differences among groups were assessed by one-way ANOVA analysis. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

(E) Liver histopathology assessed by H&E staining (magnification, 200×), scale bar: 100 μm.

(F) NAFLD active score. Data are represented as mean ± SEM (n = 6 in each group). Differences among groups were assessed by one-way ANOVA analysis. ∗∗p < 0.01, ∗∗∗p < 0.001.

(G) Liver fibrosis determined by Masson staining (magnification, 200×), scale bar: 100 μm.

(H) Liver fibrosis score. Data are represented as mean ± SEM (n = 6 in each group). Differences among groups were assessed by one-way ANOVA analysis. ∗∗∗p < 0.001. NC, normal control; HFD-C, high fat diet control; Met, metformin; ALT, alanine aminotransferase; AST, aspartate aminotransferase.